Medtronic (NYSE:MDT) today launched a study to evaluate the safety and efficacy of its Resolute Onyx drug-eluting stent for the treatment of bifurcation lesions in patients with coronary artery disease.
The medtech giant said that bifurcation lesions make up nearly 20% of all percutaneous coronary interventions. The assessment of DES tech in this patient group is part of Medtronic’s post-approval study of its Resolute Onyx device.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic launches study of drug-eluting stent as treatment for bifurcation lesions appeared first on MassDevice.